GSA Capital Partners’s Cytek Biosciences CTKB Stock Holding History

GSA Capital Partners’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$477K	Buy	+109,116	New	+$515K	0.03%	950
2025 Q4	–	Sell	-109,098	Closed	-$379K	–	1734
2025 Q3	$379K	Buy	109,098 +73,932	+210%	+$278K	0.03%	1049
2025 Q2	$120K	Sell	35,166 -43,896	-56%	-$146K	0.01%	1596
2025 Q1	$317K	Buy	+79,062	New	+$410K	0.03%	1111
2024 Q4	–	Sell	-37,884	Closed	-$210K	–	1676
2024 Q3	$210K	Buy	37,884 +23,237	+159%	+$132K	0.02%	1398
2024 Q2	$82K	Buy	+14,647	New	+$88K	0.01%	1542
2022 Q3	–	Sell	-73,743	Closed	-$791K	–	1576
2022 Q2	$791K	Buy	+73,743	New	+$734K	0.12%	236

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GSA Capital Partners's CTKB Position: Q1 2026 in Review

GSA Capital Partners opened a new position in Cytek Biosciences (CTKB) in Q1 2026: 109,116 shares worth $477K. The stake represents 0.03% of the portfolio and ranks #950 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in CTKB as recently as Q3 2025.

GSA Capital Partners first reported a position in CTKB in Q2 2022 and has held it in 7 quarters since. The position peaked at $791K in Q2 2022. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

GSA Capital Partners held 109,116 shares of Cytek Biosciences worth $477K as of Q1 2026.
Cytek Biosciences was a new GSA Capital Partners position in Q1 2026.
Cytek Biosciences made up 0.03% of GSA Capital Partners's portfolio in Q1 2026, its #950 holding.
GSA Capital Partners first reported a position in Cytek Biosciences in Q2 2022 and has held it in 7 quarters since.
GSA Capital Partners's Cytek Biosciences position peaked at $791K in Q2 2022.
165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.